Page last updated: 2024-08-17

adenosine monophosphate and prasugrel hydrochloride

adenosine monophosphate has been researched along with prasugrel hydrochloride in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	18 (28.13)	29.6817
2010's	41 (64.06)	24.3611
2020's	5 (7.81)	2.80

Authors

Authors	Studies
Gurbel, PA; Tantry, US	1
Cattaneo, M	3
Rich, JD; Wiviott, SD	1
Angiolillo, DJ	1
Buckland, RJ; Jakubowski, JA; Judge, HM; Storey, RF; Sugidachi, A	1
Dovlatova, NL; Heptinstall, S; Jakubowski, JA; Sugidachi, A	1
Dovlatova, N; Heptinstall, S; Johnson, A	1
Barker, CM; Price, MJ	1
Angiolillo, DJ; Capranzano, P	1
Eikelboom, JW; Hirsh, J; Raju, NC	1
Abu-Fadel, M; Norgard, NB	1
Akram, F; Akram, S; Postuła, M	1
Angiolillo, DJ; Bhatt, DL; Gurbel, PA; Jennings, LK	1
Butt, M; Lip, GY; Shantsila, E; Siddique, A	1
Blade, CL; Das, K; Das, P; Doby, JB; Mukherjee, D; Oliphant, CS	1
Franchini, M; Mannucci, PM	1
Banach, M; Hannam, S; Kowalczyk, M; Mikhailidis, DP; Rysz, J	1
del Río, A; Heras, M	1
Jilma, B; Krumphuber, J; Siller-Matula, JM	1
Cattaneo, M; Podda, GM	1
Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; Nylander, S; van Giezen, H; White, AE	1
Fox, SC; Glenn, JR; Heptinstall, S; Iyú, D; White, AE	1
Frey, N; Ivandic, B	1
Ağırbaşlı, M; Cinçin, A; Güvenç, H	1
Storey, RF	1
Bellemain, A; Collet, JP; Ecollan, P; Montalescot, G; Silvain, J	1
Cattaneo, GJ; Cattaneo, M; Podda, GM	1
Moliterno, DJ; Rajan, L	1
Böhm, M; Schirmer, SH	1
Contractor, H; Ruparelia, N	1
Barn, K; Steinhubl, SR	1
Bernlochner, I; Sibbing, D	1
Augoustides, JG; Lane, B; Patel, PA	1
Alves, CM; Caixeta, AM; Carvalho, AC; Carvalho, L; Chan, M; Falcão, FJ	1
Aylward, PE; Sinhal, AR	1
Jover, E; Tello-Montoliu, A; Valdés, M	1
Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ	1
Sabouret, P; Taiel-Sartral, M	1
Angiolillo, DJ; Bass, TA; Cho, JR; Darlington, A; Desai, B; Ferreiro, JL; Franchi, F; Guzman, LA; Muñiz-Lozano, A; Patel, R; Rollini, F; Tello-Montoliu, A; Zenni, MM	1
Caldeira, D; Ferreira, JJ; Pinto, FJ	1
Adamski, P; Fabiszak, T; Grześk, G; Koziński, M; Kubica, J; Navarese, EP; Ostrowska, M; Paciorek, P	1
Gogo, P; Keating, FK; Raza, SS; Schneider, DJ; Seecheran, N	1
Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L	1
Buckland, RJ; Jakubowski, JA; Judge, HM; Storey, RF	1
Bolek, T; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M	1
Basabe-Desmonts, L; Gilmartin, N; Jose, B; Kenny, D; Kent, NJ; McCluskey, P; Ricco, AJ; Somers, M	1
Angiolillo, DJ; Capodanno, D	1
Drebes, A; Klonaris, C; Liakakos, T; Matheiken, S; Patelis, N	1
Bhatt, DL; Fuster, V; Gersh, BJ; Lennon, RJ; Narula, J; Rihal, CS; Singh, M; Stone, GW	1
Lipinski, MJ; Torguson, R; Waksman, R; Westman, PC	1
Frelinger, AL; Gerrits, AJ; Jakubowski, JA; Michelson, AD; Sugidachi, A	1
Amann, M; Bömicke, T; Ferenc, M; Hauschke, D; Hochholzer, W; Kleiner, P; Löffelhardt, N; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM; Younas, I	1
Ferenc, M; Hochholzer, W; Löffelhardt, N; Mashayekhi, K; Neumann, FJ; Nührenberg, T; Stratz, C; Trenk, D; Valina, CM	1
Boncler, M; Polak, D; Rozalski, M; Watala, C; Wolska, N; Wzorek, J	1
Capodanno, D; Capranzano, P	1
Alexopoulos, D; Lianos, I; Mpahara, A; Varlamos, C	1
Boncler, M; Gapinska, M; Polak, D; Przygodzki, T; Rozalski, M; Watala, C; Wolska, N; Wzorek, J	1
Avvedimento, M; Billinger, M; Campo, G; Cirillo, P; Esposito, G; Gargiulo, G; Gragnano, F; Heg, D; Hunziker, L; Manavifar, N; Minuz, P; Nagler, M; Piccolo, R; Tebaldi, M; Valgimigli, M; Wahl, A; Windecker, S	1
Angiolillo, DJ; Bhatt, DL; Stone, GW	1
Gargiulo, G; Nagler, M; Valgimigli, M	1
Bonda, TA; Karolczak, K; Kramkowski, K; Polak, D; Przygodzki, T; Talar, M; Watala, C; Wojkowska, DW; Wolska, N	1
Angiolillo, DJ; Bhatt, DL; Davidson-Ray, L; Dell'Anna, C; Diaz, M; Edwards, L; El-Sabae, H; Garratt, KN; Ohman, EM; Rymer, JA; Salahuddin, K; Tasissa, G; Waksman, R; Wang, TY; Washam, JB	1

Reviews

43 review(s) available for adenosine monophosphate and prasugrel hydrochloride

Article	Year
Aspirin and clopidogrel resistance: consideration and management. Journal of interventional cardiology, 2006, Volume: 19, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2006
Platelet P2 receptors: old and new targets for antithrombotic drugs. Expert review of cardiovascular therapy, 2007, Volume: 5, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine	2007
New antiplatelet therapies for acute coronary syndromes. Current cardiology reports, 2007, Volume: 9, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Blood Platelets; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Treatment Outcome	2007
ADP receptor antagonism: what's in the pipeline? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2007, Volume: 7, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronary Disease; Humans; Membrane Proteins; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2007
Pharmacology of emerging novel platelet inhibitors. American heart journal, 2008, Volume: 156, Issue:2 Suppl Topics: Adenosine; Adenosine Monophosphate; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor	2008
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:12 Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2008
Future prospects in anti-platelet therapy: a review of potential P2Y12 and thrombin receptor antagonists. Recent patents on cardiovascular drug discovery, 2008, Volume: 3, Issue:3 Topics: Adenosine Monophosphate; Animals; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Thrombosis	2008
Current problems, new opportunities and future directions of anti-platelet therapy - increasing role of novel antiplatelet agents in cardiovascular diseases. Recent patents on cardiovascular drug discovery, 2009, Volume: 4, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Imines; Lactones; Patents as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptor, PAR-1; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine	2009
Advances in antiplatelet therapy: agents in clinical development. The American journal of cardiology, 2009, Feb-02, Volume: 103, Issue:3 Suppl Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Signal Transduction; Thiophenes; Ticagrelor; Treatment Outcome	2009
New antiplatelet drugs: beyond aspirin and clopidogrel. International journal of clinical practice, 2009, Volume: 63, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Emerging P2Y12 receptor antagonists: role in coronary artery disease. Current vascular pharmacology, 2010, Volume: 8, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Animals; Coronary Artery Disease; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor	2010
New P2Y12 blockers. Journal of thrombosis and haemostasis : JTH, 2009, Volume: 7 Suppl 1 Topics: Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Treatment Outcome	2009
New antiplatelet agents: why they are needed. European journal of internal medicine, 2009, Volume: 20, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prodrugs; Propionates; Pyridines; Thiophenes; Ticagrelor	2009
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors? Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:12 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as Topic; Clopidogrel; Hemorrhage; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2009
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2009, Volume: 9 Suppl 1 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticagrelor; Ticlopidine	2009
Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British journal of pharmacology, 2010, Feb-01, Volume: 159, Issue:3 Topics: Adenosine; Adenosine Monophosphate; Benzofurans; Blood Platelets; Carbamates; Clinical Trials as Topic; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Receptor, PAR-1; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Ticlopidine; von Willebrand Factor	2010
State of the art of new P2Y12 antagonists. Internal and emergency medicine, 2010, Volume: 5, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2010
[New approaches and indications for the analysis of platelet function in cardiology]. Hamostaseologie, 2011, May-02, Volume: 31, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine	2011
[Novel agents in antiplatelet therapy]. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2010, Volume: 38, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine	2010
Bleeding manifestations of congenital and drug-induced defects of the platelet P2Y12 receptor for adenosine diphosphate. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2011
Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thrombosis and haemostasis, 2011, Volume: 105 Suppl 1 Topics: Adenosine; Adenosine Monophosphate; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Piperazines; Platelet Activation; Prasugrel Hydrochloride; Protein Binding; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2011
[Myocardial infarction: Role of new antiplatelet agents]. Presse medicale (Paris, France : 1983), 2011, Volume: 40, Issue:6 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Disease Management; Drug Resistance; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Reperfusion; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine; Time Factors	2011
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists]. Recenti progressi in medicina, 2011, Volume: 102, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine	2011
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? Current cardiology reports, 2011, Volume: 13, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine	2011
[Update on anti-platelet therapy]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:23 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Thrombolytic Therapy; Ticagrelor	2011
Advances in antiplatelet therapy for acute coronary syndromes. Postgraduate medical journal, 2012, Volume: 88, Issue:1041 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2012
A brief review of the past and future of platelet P2Y12 antagonist. Coronary artery disease, 2012, Volume: 23, Issue:6 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Stents; Sulfonamides; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine	2012
Thienopyridines and other ADP-receptor antagonists. Handbook of experimental pharmacology, 2012, Issue:210 Topics: Adenosine; Adenosine Monophosphate; Animals; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine	2012
Progress in platelet blockers: the target is the P2Y12 receptor. Journal of cardiothoracic and vascular anesthesia, 2013, Volume: 27, Issue:3 Topics: Adenosine; Adenosine Monophosphate; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor	2013
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes. Clinical therapeutics, 2013, Volume: 35, Issue:8 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2013
[New antiplatelet drugs in coronary artery disease]. Medicina clinica, 2014, Dec-09, Volume: 143, Issue:11 Topics: Adenosine; Adenosine Monophosphate; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Double-Blind Method; Dyspnea; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Proteinase-Activated; Thiophenes; Ticagrelor; Treatment Outcome	2014
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. Atherosclerosis, 2014, Volume: 233, Issue:2 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Intravenous; Multicenter Studies as Topic; Myocardial Infarction; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Stents; Stroke; Sulfonamides; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine	2014
New antiplatelet agents in the treatment of acute coronary syndromes. Archives of cardiovascular diseases, 2014, Volume: 107, Issue:3 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Dyspnea and reversibility profile of P2Y₁₂ antagonists: systematic review of new antiplatelet drugs. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:4 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Dyspnea; Humans; Incidence; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine	2014
Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. Thrombosis and haemostasis, 2014, Volume: 112, Issue:2 Topics: Adenosine; Adenosine Monophosphate; Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Clopidogrel; Drug Therapy, Combination; Humans; Off-Label Use; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Signal Transduction; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome	2014
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? American heart journal, 2014, Volume: 168, Issue:5 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin	2014
Type 2 Diabetes and ADP Receptor Blocker Therapy. Journal of diabetes research, 2016, Volume: 2016 Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus, Type 2; Drug Resistance; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome	2016
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients. Expert review of cardiovascular therapy, 2016, Volume: 14, Issue:7 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine	2016
Antiplatelet Treatment in Peripheral Arterial Disease: The Role of Novel Antiplatelet Agents. Current pharmaceutical design, 2016, Volume: 22, Issue:29 Topics: Adenosine; Adenosine Monophosphate; Imines; Lactones; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Quinazolinones; Sulfonamides; Ticagrelor	2016
Antithrombotic Approaches in Acute Coronary Syndromes: Optimizing Benefit vs Bleeding Risks. Mayo Clinic proceedings, 2016, Volume: 91, Issue:10 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Antithrombins; Clinical Trials as Topic; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Genotype; Hemorrhage; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polymorphism, Genetic; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor	2016
A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis. Cardiovascular revascularization medicine : including molecular interventions, 2017, Volume: 18, Issue:2 Topics: Adenosine; Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Network Meta-Analysis; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome	2017
Switching between P2Y Vascular pharmacology, 2019, Volume: 116 Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Cardiovascular Diseases; Clinical Decision-Making; Clopidogrel; Drug Substitution; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Treatment Outcome	2019
P2Y12 inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes. Expert review of cardiovascular therapy, 2019, Volume: 17, Issue:10 Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Ticagrelor	2019

Trials

5 trial(s) available for adenosine monophosphate and prasugrel hydrochloride

Article	Year
Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients. JACC. Cardiovascular interventions, 2014, Volume: 7, Issue:4 Topics: Adenosine Monophosphate; Aged; Blood Platelets; Cell Adhesion Molecules; Coronary Artery Disease; Drug Administration Schedule; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Thiophenes; Time Factors	2014
Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coronary artery disease, 2015, Volume: 26, Issue:1 Topics: Adenosine Monophosphate; Administration, Oral; Aged; Coronary Artery Disease; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Time Factors; Treatment Outcome	2015
Randomized Comparison of Oral P2Y JACC. Cardiovascular interventions, 2017, 01-23, Volume: 10, Issue:2 Topics: Adenosine; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Disease; Drug Substitution; Female; Germany; Humans; Infusions, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome	2017
Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor. Thrombosis and haemostasis, 2018, Volume: 118, Issue:2 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Administration, Oral; Aged; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Ticagrelor	2018
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Journal of cardiovascular translational research, 2021, Volume: 14, Issue:1 Topics: Adenosine Monophosphate; Aged; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Tirofiban	2021

Other Studies

16 other study(ies) available for adenosine monophosphate and prasugrel hydrochloride

Article	Year
The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses. Platelets, 2008, Volume: 19, Issue:2 Topics: Adenosine Monophosphate; Adult; Annexin A5; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Cytoplasmic Granules; Humans; In Vitro Techniques; Microfilament Proteins; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2008
The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. Journal of thrombosis and haemostasis : JTH, 2008, Volume: 6, Issue:7 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cells, Cultured; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2008
Multiple electrode aggregometry and P2Y(12) antagonists. Thrombosis and haemostasis, 2008, Volume: 99, Issue:6 Topics: Adenosine Diphosphate; Adenosine Monophosphate; Anticoagulants; Clopidogrel; Dose-Response Relationship, Drug; Electrodes; Equipment Design; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticlopidine	2008
Antiplatelet therapy in acute coronary syndromes. Current cardiology reports, 2008, Volume: 10, Issue:4 Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine	2008
Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function. Thrombosis and haemostasis, 2011, Volume: 105, Issue:1 Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Cells, Cultured; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, G-Protein-Coupled; Thiophenes; Ticagrelor	2011
Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist. Arteriosclerosis, thrombosis, and vascular biology, 2011, Volume: 31, Issue:2 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Erythrocytes; Humans; Microfilament Proteins; Phosphoproteins; Phosphorylation; Piperazines; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Receptors, Thrombin; Thiophenes; Ticagrelor	2011
P2Y12 platelet receptors: importance in percutaneous coronary intervention. Arquivos brasileiros de cardiologia, 2013, Volume: 101, Issue:3 Topics: Adenosine; Adenosine Monophosphate; Humans; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thienopyridines; Thiophenes; Ticagrelor	2013
Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y12 receptors in vitro. Platelets, 2016, Volume: 27, Issue:3 Topics: Adenosine Monophosphate; Binding, Competitive; Clopidogrel; Humans; In Vitro Techniques; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine	2016
Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs. Langmuir : the ACS journal of surfaces and colloids, 2016, Mar-22, Volume: 32, Issue:11 Topics: Abciximab; Adenosine; Adenosine Monophosphate; Animals; Antibodies, Monoclonal; Cattle; Clopidogrel; Dimethylpolysiloxanes; Equipment Design; Fibrinogen; Humans; Immunoglobulin Fab Fragments; Lab-On-A-Chip Devices; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Powders; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Serum Albumin, Bovine; Ticagrelor; Ticlopidine	2016
Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. Journal of thrombosis and haemostasis : JTH, 2017, Volume: 15, Issue:5 Topics: Adenosine; Adenosine Monophosphate; Blood Platelets; Cell Adhesion Molecules; Dose-Response Relationship, Drug; Humans; Kinetics; Microfilament Proteins; P-Selectin; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Ticagrelor	2017
Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y Vascular pharmacology, 2019, Volume: 113 Topics: Adenosine; Adenosine A2 Receptor Agonists; Adenosine Monophosphate; Adult; Blood Platelets; Dose-Response Relationship, Drug; Female; Furans; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Signal Transduction; Young Adult	2019
Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y Molecules (Basel, Switzerland), 2019, Dec-28, Volume: 25, Issue:1 Topics: Adenosine Monophosphate; Drug Resistance; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P1 Receptor Agonists; Receptors, Purinergic P2Y12; Thrombosis	2019
Letter by Angiolillo et al Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial". Circulation, 2021, 03-30, Volume: 143, Issue:13 Topics: Adenosine Monophosphate; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban	2021
Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial". Circulation, 2021, 03-30, Volume: 143, Issue:13 Topics: Adenosine Monophosphate; Humans; Prasugrel Hydrochloride; ST Elevation Myocardial Infarction; Tirofiban	2021
Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus. International journal of molecular sciences, 2021, Mar-17, Volume: 22, Issue:6 Topics: Adenosine Monophosphate; Adenosine-5'-(N-ethylcarboxamide); Adult; Animals; Antithrombins; Blood Pressure; Blood-Brain Barrier; Chlorides; Diastole; Female; Ferric Compounds; Fibrinogen; Humans; Laser-Doppler Flowmetry; Male; Mice, Inbred C57BL; Permeability; Platelet Activation; Platelet Aggregation; Prasugrel Hydrochloride; Purinergic P1 Receptor Agonists; Purinergic P2Y Receptor Antagonists; Systole; Thrombosis	2021
Cangrelor Use Patterns and Transition to Oral P2Y Journal of the American Heart Association, 2022, 06-07, Volume: 11, Issue:11 Topics: Adenosine Monophosphate; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Treatment Outcome	2022